Navigation Links
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Date:2/12/2008

S-108 is a targeted cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic drug, doxorubicin, in the cells. Therefore, since they target specific cells, cytotoxic conjugates are postulated to be less toxic, have less side-effects and are more effective in vivo than the respective non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.

About ovarian and endometrial cancer

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnosis in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year.

(Source: Gynecologic Oncology, Volume 92, Issue 3, March 2004, Pages 819-826)

Cancer of the endometrium is the most common gynaecologic malignancy and accounts for 6% of all cancers in women. The majority of the cases occur in postmenopausal women, with the largest number of women developing their cancers during the sixth decade. Approximately 38,000 new cases and 9,000 deaths from this disease are estimated annually in Europe.
(Source: Annals of Oncology 15:1149-1150, 2004)

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases an
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
2. AEterna Zentaris Announces Outcome of Managements Strategic Review
3. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Immtech Reports Fiscal Third Quarter 2008 Results
7. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
10. Bunge Reports Fourth Quarter Net Income of $245 Million
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Ontotext S4 , The ... Ontotext . Now the same enterprise hardened text ... and unstructured data is available to start-ups and mid-size ... technology. Organizations that do not have resources to evaluate ... use S4 since there is no need for on ...
(Date:8/20/2014)... Clintrax Global, Inc., a worldwide provider ... Raleigh, NC , recently announced the addition ... of Administration. As Vice President ... including their alignment with company objectives and policies.  ... an HR executive, specializing in needs assessments, customer ...
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... San Francisco, CA (PRWEB) August 20, 2014 ... Medicine Conference is being held on October 29-30 ... fresh perspectives from industry, academic and government researchers and ... remaining in the space. , In the twelve ... than one hundred therapies have been introduced with pharmacogenetic ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... Waukesha, Wis. - GE Healthcare has ... Research Excellence in Breast Cancer Imaging within the ... , ,With funding from GE Healthcare, a $17 billion ... is designed to advance and commercialize research and technology ...
... a meeting with U.S. Health and Human Services ... and healthcare organizations pledged to support health information technology ... health information technology products used by their health plans. ... effort to support a national initiative aimed at improving ...
... admitted his crystal ball may be a little cloudy, but he ... woes may have already trickled out in anticipation of the ... his Senate colleague and a software executive, isn`t sure the worst ... that the audit on state IT projects should be a catalyst ...
Cached Biology Technology:Wisconsin firms pledge to support healthcare IT standards 2Is the worst over for state technology failures? 2
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
(Date:8/20/2014)... (HCI) at the University of Utah have identified and ... the unregulated enzyme driving the blood cancer chronic myeloid ... 6,000 new cases of CML will be diagnosed in ... inhibitors (TKIs), target BCR-ABL and are effective at controlling ... it in a way that allows patients to get ...
(Date:8/20/2014)... this image of the Para and Mato Grosso states ... intentionally set in order to deforest the land. Deforestation ... trees where the land is thereafter converted to a ... to farms, ranches, or urban use. The herringbone-patterned tan ... Rainforest in the middle of the image are evidence ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... forming the droplets that make up clouds, a little ... much. And that,s good news for reducing the uncertainty ... essential for accurate climate modeling, and understanding cloud formation ... form when water vapor is attracted to particles floating ...
... name by successfully transplanting bioengineered stem cell-based trachea, composed of ... the technique to recreate more complex tissues, such as the ... lungs. He has also made an experimental attempt to regenerate ... news he will be presenting during his seminar at the ...
... national synchrotron facility, Diamond Light Source, is now the first ... 3 including serious viruses such as those responsible for ... analysed at atomic and molecular level using synchrotron light. This ... levels of detail and this new facility extends that capability ...
Cached Biology News:The role of goop: Research shows pollution doesn't change the rate of droplet formation 2The role of goop: Research shows pollution doesn't change the rate of droplet formation 3Stem cell-based bioartificial tissues and organs 2Diamond sheds light on basic building blocks of life 2Diamond sheds light on basic building blocks of life 3
... anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... dependent dilution. ICC: Use at an assay dependent ... - 10 ug/ml, this concentration is determined using ... weight: 40 kDa. Not tested in other applications. ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Anti human PPAR gamma2 mouse monoclonal antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Biology Products: